Weight loss drugs are changing the game, Eli Lilly exec says — but many still can't get them
Obesity is a major global health crisis, especially in the United States, but newer weight-loss drugs like Eli Lilly’s (LLY) Zepbound could offer a long-awaited solution — if they become more accessible.
Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...
Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...
Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...
Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by ...
Eli Lilly CEO said he believed the company could find “significant common cause” with the Trump administration, even if there ...
Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...
Eli Lilly blamed the shortfall on lower-than-anticipated demand for its weight-loss drugs. Indeed, the drug maker ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback